Table 2.
Fatal adverse events by specific type
| Adverse events | Events on the MTA arms | Events on control arms |
|---|---|---|
| Death not otherwise specified | 628,30,33 | 132 |
| Hepatic failure | 1025,27–29,32,33 | 525,27 |
| Myocardial infarction/ischemia | 329,31 | 132 |
| Upper gastrointestinal hemorrhage | 330 | 230 |
| Intracranial hemorrhage | 332 | 0 |
| Encephalopathy | 328 | 0 |
| Renal failure | 330,33 | 130 |
| Pulmonary infection, pneumonitis | 325,27,30 | 125 |
| Gastric perforation | 130 | 0 |
| Febrile neutropenia | 0 | 129 |
| Thrombosis or embolism | 0 | 229,33 |
| Acidosis | 128 | 0 |
| Cerebral edema | 128 | 0 |
| Cerebrovascular accident | 130 | 0 |
| Interstitial lung disease | 130 | 0 |
| Peritonitis | 227,30 | 0 |
| Respiratory failure | 130 | 130 |
| Multiorgan failure | 133 | 130 |
| Sepsis, septic shock | 225,33 | 133 |
Abbreviation: MTA, molecular targeted agent.